Breaking: Merck \u0026 Co (NYSE:MRK) Outperform Rating Maintained at BMO Capital Today; The Price Objective Given is $65

February 15, 2018 - By simple simple

 Breaking: Merck \u0026 Co (NYSE:MRK) Outperform Rating Maintained at BMO Capital Today; The Price Objective Given is $65

Investors sentiment decreased to 1.06 in Q3 2017. Its down 0.01, from 1.07 in 2017Q2. It dived, as 46 investors sold Merck & Co., Inc. shares while 619 reduced holdings. 106 funds opened positions while 598 raised stakes. 1.96 billion shares or 0.47% more from 1.95 billion shares in 2017Q2 were reported.

Central Securities invested 2.19% in Merck & Co., Inc. (NYSE:MRK). Bradley Foster Sargent Inc Ct holds 751,895 shares or 1.83% of its portfolio. Mariner Wealth Advsrs Limited Liability Company has invested 0.12% in Merck & Co., Inc. (NYSE:MRK). Kayne Anderson Rudnick Invest Mngmt Limited Liability Company accumulated 99,267 shares. Whitnell has 15,975 shares for 0.45% of their portfolio. Horan Cap Advisors Ltd reported 3,230 shares. Ironwood Investment Management Limited Liability Corporation, Massachusetts-based fund reported 5,459 shares. Psagot House Limited reported 67,104 shares or 0.18% of all its holdings. Ntv Asset Mngmt Limited Liability Company invested 0.39% in Merck & Co., Inc. (NYSE:MRK). Broderick Brian C invested in 0.83% or 35,944 shares. Nikko Asset Management Americas holds 0.37% or 118,400 shares. Spectrum Mngmt Incorporated holds 0.66% of its portfolio in Merck & Co., Inc. (NYSE:MRK) for 31,710 shares. Guggenheim Cap Ltd holds 1.40M shares. Rodgers Brothers Incorporated reported 21,551 shares stake. 6,901 were accumulated by Pinnacle Wealth Mngmt Advisory Gp Ltd Liability.

Merck \u0026 Co (NYSE:MRK) Rating Reaffirmed

BMO Capital now has a $65 PT on shares of Merck \u0026 Co (NYSE:MRK). The PT suggests a potential upside of 17.99 % from the current price of Merck \u0026 Co (NYSE:MRK). This rating was released in an analyst report on Wednesday, 14 February.

Investors sentiment decreased to 1.06 in Q3 2017. Its down 0.01, from 1.07 in 2017Q2. It dived, as 46 investors sold Merck & Co., Inc. shares while 619 reduced holdings. 106 funds opened positions while 598 raised stakes. 1.96 billion shares or 0.47% more from 1.95 billion shares in 2017Q2 were reported.

Central Securities invested 2.19% in Merck & Co., Inc. (NYSE:MRK). Bradley Foster Sargent Inc Ct holds 751,895 shares or 1.83% of its portfolio. Mariner Wealth Advsrs Limited Liability Company has invested 0.12% in Merck & Co., Inc. (NYSE:MRK). Kayne Anderson Rudnick Invest Mngmt Limited Liability Company accumulated 99,267 shares. Whitnell has 15,975 shares for 0.45% of their portfolio. Horan Cap Advisors Ltd reported 3,230 shares. Ironwood Investment Management Limited Liability Corporation, Massachusetts-based fund reported 5,459 shares. Psagot House Limited reported 67,104 shares or 0.18% of all its holdings. Ntv Asset Mngmt Limited Liability Company invested 0.39% in Merck & Co., Inc. (NYSE:MRK). Broderick Brian C invested in 0.83% or 35,944 shares. Nikko Asset Management Americas holds 0.37% or 118,400 shares. Spectrum Mngmt Incorporated holds 0.66% of its portfolio in Merck & Co., Inc. (NYSE:MRK) for 31,710 shares. Guggenheim Cap Ltd holds 1.40M shares. Rodgers Brothers Incorporated reported 21,551 shares stake. 6,901 were accumulated by Pinnacle Wealth Mngmt Advisory Gp Ltd Liability.

Merck & Co., Inc. (NYSE:MRK) Ratings Coverage

Among 24 analysts covering Merck & Co. Inc. (NYSE:MRK), 17 have Buy rating, 0 Sell and 7 Hold. Therefore 71% are positive. Merck & Co. Inc. has $7400 highest and $50 lowest target. $65.28’s average target is 18.50% above currents $55.09 stock price. Merck & Co. Inc. had 79 analyst reports since August 13, 2015 according to SRatingsIntel. Deutsche Bank maintained it with “Hold” rating and $66 target in Monday, July 17 report. Cowen & Co maintained it with “Hold” rating and $70.0 target in Friday, November 3 report. The firm has “Buy” rating by Citigroup given on Monday, October 30. BMO Capital Markets maintained the stock with “Outperform” rating in Thursday, October 12 report. On Wednesday, October 18 the stock rating was upgraded by Citigroup to “Buy”. As per Tuesday, January 16, the company rating was maintained by Jefferies. The stock has “Market Perform” rating by BMO Capital Markets on Monday, July 18. The stock of Merck & Co., Inc. (NYSE:MRK) earned “Outperform” rating by Credit Suisse on Friday, September 8. The firm has “Hold” rating by Jefferies given on Thursday, July 14. The stock of Merck & Co., Inc. (NYSE:MRK) earned “Buy” rating by Societe Generale on Wednesday, April 6.

The stock increased 0.35% or $0.19 during the last trading session, reaching $55.09. About 3.78 million shares traded. Merck & Co., Inc. (NYSE:MRK) has risen 16.86% since February 15, 2017 and is uptrending. It has outperformed by 0.16% the S&P500.

Merck & Co., Inc. provides healthcare solutions worldwide. The company has market cap of $150.09 billion. It operates in four divisions: Pharmaceutical, Animal Health, Healthcare Services, and Alliances divisions. It has a 59.24 P/E ratio. The firm offers therapeutic agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal and intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

More notable recent Merck & Co., Inc. (NYSE:MRK) news were published by: Investorplace.com which released: “Merck & Co., Inc. Stock Could Still Soar Another 10% From Here” on January 18, 2018, also Nasdaq.com with their article: “Merck & Co Inc. Announces Advance In Q4 Profit” published on February 02, 2018, Seekingalpha.com published: “Merck: Keytruda Remains Key” on February 04, 2018. More interesting news about Merck & Co., Inc. (NYSE:MRK) were released by: Investorplace.com and their article: “Merck & Co., Inc.’s Rally Could Burn Investors” published on January 19, 2018 as well as Bloomberg.com‘s news article titled: “Merck Will End Alzheimer’s Trial as Alternative Approach Fails” with publication date: February 13, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.